Gliatech (GLIA) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (675)	3/13/1999 2:20:00 PM
From: NeuroInvestment	Read Replies (2) of 2001

Rick: Just a quick comment due to time constraints: the juxtaposition of the two reports illustrates the multiple ways that the serotonin system interacts with other neurotransmitter systems. The French report regarding 5HT-2A blockade as stimulating H3 antagonism is the same dynamic as you noted in a previous citation of an (Italian?) study. The fact that atypical antipsychotics seem to exert pro-cognitive effects via the histamine system supports the principle of H3 antagonism being pursued by GLIA--that you can upregulate cognition that way. The second citation seems irrelevant to the H3/GLIA issue: it is believed that 5HT-2 blockade somehow ameliorates the Parkinsonian symptoms associated with D2 blockade caused by older generation antipsychotics, permitting psychosis tx with less Parkinsonian sx. By implication, Parkinsonian sx due to genuine Parkinson's rather than the side effects of antipsychotic tx also appears to be ameliorated by Clozapine's action on the serotonin system. Thus modulating serotonin receptors is shown to affect histaminergic and dopaminergic systems 'downstream.' The first is pertinent to GLIA, the second, so far as I can tell, is not. NeuroInvestment (www.neuroinvestment.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next